Tue, Jul 29, 2014, 8:34 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Elan Corporation, plc Message Board

  • oxledge oxledge Mar 12, 2006 8:47 PM Flag

    Focus on the task at hand


    Dont listen to the bashers. I have not seen one reasonable post from them. They are all idiots simply trying to manipulate the ELN price in the short term. We must continue to focus on the task at hand.

    1. Contact the FDA by letter, phone or email. Tell them that you want Ty approved immediately (not enev a week delay). Tell them that you want Ty to be approved for FIRST LINE THERAPY. Nothing short of that is acceptable. Tell them that you do not want any undue restrcitions on the use of Ty. Tell them that Ty does not cuase PML. Avonex does. Ty alone has no indicences of PML.

    2. Tell every neuro and MS sufferer you may know to get on board with Ty. Direct them to the scientific data recently presented and the FDA AC meeting results. Spread the word to those with this awful disease. Get them off the crummy existing therapies and get them on something that really works, Ty.

    3. If you know any infusion clinics or people that work at any, tell them about Ty and get them on the case.

    4. Call, email, or write your local and state politicians and national congressmen and congresswomen. Tell them that we need Ty as a First Line Therapy. Ty will dramatically lower our nation's overall healthcare costs and bring people currently disabled back into the workforce. You get your politican on board and Ty will means votes for these people. an you imagine all the great press as your local politican supports this drug and is seen helping those in his ir her district. This is going to make huge headlines. Eg...for those in New york, email Shumer and Hillary. Tell them that we need Ty NOW as first line therapy.


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.